210 related articles for article (PubMed ID: 22629421)
1. Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia.
Lee S; Han MJ; Lee KS; Back SC; Hwang D; Kim HY; Shin JH; Suh SP; Ryang DW; Kim HR; Shin MG
PLoS One; 2012; 7(5):e37571. PubMed ID: 22629421
[TBL] [Abstract][Full Text] [Related]
2. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
Beilstein M; Silberg D
Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial DNA deletions in patients with esophagitis, Barrett's esophagus, esophageal adenocarcinoma and squamous cell carcinoma.
Keles M; Sahin I; Kurt A; Bozoglu C; Simsek G; Kabalar E; Tatar A
Afr Health Sci; 2019 Mar; 19(1):1671-1676. PubMed ID: 31148997
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
6. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
[TBL] [Abstract][Full Text] [Related]
7. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
8. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
9. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
11. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
12. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
13. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
Grady WM; Yu M
Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
15. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
[TBL] [Abstract][Full Text] [Related]
17. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
[TBL] [Abstract][Full Text] [Related]
18. [Carcinogenesis of Barrett's esophagus].
Endo T; Sugawara N; Shinomura Y
Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
[TBL] [Abstract][Full Text] [Related]
19. Structural alterations of the mucosa stroma in the Barrett's esophagus metaplasia-dysplasia-adenocarcinoma sequence.
Bobryshev YV; Killingsworth MC; Lord RV
J Gastroenterol Hepatol; 2012 Sep; 27(9):1498-504. PubMed ID: 22591183
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
